Zachariah M. DeFilipp, MD, Massachusetts General Hospital

Articles by Zachariah M. DeFilipp, MD, Massachusetts General Hospital

Treating Chronic Graft-vs-Host Disease

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Joseph H. Antin, MD, Dana-Farber Cancer Institute,Yi-Bin A. Chen, MD, Massachusetts General Hospital,Zachariah M. DeFilipp, MD, Massachusetts General Hospital

June 19th 2020

Shifting Paradigm in Treating Acute Graft-vs-Host Disease

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Joseph H. Antin, MD, Dana-Farber Cancer Institute,Yi-Bin A. Chen, MD, Massachusetts General Hospital,Zachariah M. DeFilipp, MD, Massachusetts General Hospital

June 19th 2020

Graft-vs-Host Disease Prophylaxis Clinical Trials

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Joseph H. Antin, MD, Dana-Farber Cancer Institute,Yi-Bin A. Chen, MD, Massachusetts General Hospital,Zachariah M. DeFilipp, MD, Massachusetts General Hospital

June 19th 2020

Special Transplant Situations

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Joseph H. Antin, MD, Dana-Farber Cancer Institute,Yi-Bin A. Chen, MD, Massachusetts General Hospital,Zachariah M. DeFilipp, MD, Massachusetts General Hospital

June 19th 2020

Risk Factors for Graft-vs-Host Disease

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Joseph H. Antin, MD, Dana-Farber Cancer Institute,Yi-Bin A. Chen, MD, Massachusetts General Hospital,Zachariah M. DeFilipp, MD, Massachusetts General Hospital

June 19th 2020

Overview of Graft-Vs-Host Disease

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Joseph H. Antin, MD, Dana-Farber Cancer Institute,Yi-Bin A. Chen, MD, Massachusetts General Hospital,Zachariah M. DeFilipp, MD, Massachusetts General Hospital

June 19th 2020

Members of the Transplant Team

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Joseph H. Antin, MD, Dana-Farber Cancer Institute,Yi-Bin A. Chen, MD, Massachusetts General Hospital,Zachariah M. DeFilipp, MD, Massachusetts General Hospital

June 19th 2020

Timing of Referral for Transplant

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Joseph H. Antin, MD, Dana-Farber Cancer Institute,Yi-Bin A. Chen, MD, Massachusetts General Hospital,Zachariah M. DeFilipp, MD, Massachusetts General Hospital

June 19th 2020

Clinical Trial Investigation: Where to Go From Here

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

The Future of GvHD: Promising Agents in Development

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

GvHD Management Recommendations

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

REACH2 Trial: Practical Implications and AE Management

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

Treatment for Steroid-Refractory GVHD: REACH2

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

When to Initiate Second-Line Therapy

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

Second-Line Therapy for GvHD

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

The Role of Steroids in GvHD Management

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

Multidisciplinary Treatment and Supportive Care

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

The Importance of Multidisciplinary Approach

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

Frontline Agents for GvHD

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

GVHD Grading and Staging

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

Risk Factors, Incidence & Typical Presentation of GvHD

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

The Nature of Acute and Chronic GvHD

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

Latest Updated Articles

Risk Factors for Graft-vs-Host Disease
June 19th 2020
Risk Factors, Incidence & Typical Presentation of GvHD
June 11th 2020
$Treatment for Steroid-Refractory GVHD: REACH2$
Treatment for Steroid-Refractory GVHD: REACH2
June 11th 2020
Special Transplant Situations
June 19th 2020
GvHD Management Recommendations
June 11th 2020
Members of the Transplant Team
June 19th 2020

Trending on OncLive

Epcoritamab Plus R-CHOP Meets PFS End Point in Newly Diagnosed DLBCL

‘Our Impact Will Be Broad and Transformative’: Wells Messersmith, MD, Takes the Reins at CU Anschutz Cancer Center

FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL

Berzosertib Plus Carboplatin Fails to Improve Responses in Pretreated mCRPC

INBRX-106 Plus Pembrolizumab Improves Responses and PFS in First-Line PD-L1–Positive HNSCC